Daniel Oliver is a co-founder and the CEO of Rejuvenate Bio, a startup out of George Church’s Lab at Harvard Medical School pioneering gene therapy solutions for age-related chronic diseases. Rejuvenate Bio’s initial focus on cardiovascular health involves a groundbreaking "one-shot"treatment for heart disease and obesity. The company's story began with rigorous validation in models featuring companion animals, leading to strategic partnerships with major players in animal health. Prior to Rejuvenate Bio, Daniel was awarded a Blavatnik Fellowship during which he co-founded Voxel8. Voxel8 was named one of the top 9 innovations at CES and one of the top 50 most innovative companies by the MIT Technology Review. Daniel received his M.B.A. from Harvard Business School and has degrees in Mechanical Engineering and Business from the California Institute of Technology.